NICE: NeuroImaging in Cessation Education
10 augusti 2020 uppdaterad av: Yale University
Effect of Showing Stroke Neuroimaging to Patients in Setting of Smoking Cessation Education on Smoking Cessation Rates in Patients With New Stroke.
The investigators aim to examine the effect on smoking cessation rate by showing stroke patients who are active smokers images of their strokes.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The investigators hypothesize that showing actual images of a patient's stroke to the participant on either brain CT or MRI will be a similarly easy to understand quantification of damage done to the participant's body.
Given the link between smoking and stroke risk, the investigators believe that providing this imaging in addition to standard smoking cessation education may improve rates of smoking cessation after stroke.
If this proves true, addition of a patient's neuroimaging to standard post-stroke smoking cessation education would be an easy method to improve smoking cessation rates in stroke patients, at minimal cost.
Studietyp
Interventionell
Inskrivning (Faktisk)
20
Fas
- Inte tillämpbar
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Age ≥18
- Active smoker, as defined: at least 100 cigarettes in their entire life, must have smoked cigarette at least once in 4 days prior to onset of stroke
- Primary ischemic or hemorrhagic stroke identified on neuroimaging (MRI DWI/ADC or CT of brain)
- Onset of stroke symptoms within 30 days to time of recruitment
- Capacity to comprehend counseling data: Each participant will be given a cognitive screening test to assess the ability to comprehend and accurately answer the medical history questionnaire (MMSE). If the participant fails this test (score < 23), they will be excluded.
- Patients discharged home or short term rehab with expectation of returning home within the study period
Exclusion Criteria:
- Patients whose stroke deficits clinically prevent them from reasonably being physically able to continue to smoke, such as bilateral upper extremity paresis, tracheostomy, GCS ≥9
- Patients with sensory aphasia that impairs comprehension
- Subarachnoid hemorrhage
- Transient ischemic attack
- Other cause of cerebral ischemia or hemorrhage not defined as primary ischemic or hemorrhagic stroke (i.e. hemorrhagic metastases)
- Patients whose stroke symptoms started >30 days from time of enrollment
- Patients discharged to acute rehab, long term acute care hospital or hospice who are unlikely to have access to cigarettes
- Patients unable to complete cognitive screening test for whom an appropriate proxy does not exist
- Patients who do not speak fluent English (given that the study largely revolves around oral education on smoking cessation, clear communication between participant and coordinator must be possible)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Standardized smoking cessation counseling
Standardized smoking cessation counseling will be provided at the participant's initial interview.
Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction.
Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit.
Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009).
Counseling will be scripted and standardized to ensure similar language with all participants.
|
Standardized smoking cessation counseling will be provided at their initial interview.
They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction.
Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit.
Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009).
Counseling will be scripted and standardized to ensure similar language with all participants.
|
|
Experimentell: Neuroimages of stroke
Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes.
Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed.
Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep.
In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking.
Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
|
Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes.
Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed.
Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep.
In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking.
Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
cessation of smoking measured by self-report collected during follow-up phone interviews.
Tidsram: 30 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking,
|
30 day follow-up visit
|
|
cessation of smoking measured by self-report collected during follow-up phone interviews.
Tidsram: 90 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking,
|
90 day follow-up visit
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
number of cigarettes smoked per day measured by self-report collected during follow-up phone interviews.
Tidsram: 30 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking,
|
30 day follow-up visit
|
|
number of cigarettes smoked per day measured by self-report collected during follow-up phone interviews.
Tidsram: 90 day follow-up visit
|
30 day and 90 day post-stroke phone interviews will be by a blinded APRN.
During these interviews, patients will be asked their smoking status.
If they are still smoking, they will be asked how much they are still smoking.
|
90 day follow-up visit
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Hardik Amin, MD, Yale University
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 januari 2017
Primärt slutförande (Faktisk)
1 juli 2020
Avslutad studie (Faktisk)
1 juli 2020
Studieregistreringsdatum
Först inskickad
10 maj 2016
Först inskickad som uppfyllde QC-kriterierna
10 maj 2016
Första postat (Uppskatta)
12 maj 2016
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
12 augusti 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 augusti 2020
Senast verifierad
1 juni 2019
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1606017908
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .